The Ministry of Health, Labor and Welfare (MHLW) appears to be ready to begin post-launch drug price adjustments based on cost-effectiveness assessments (CEAs) for the first time since the system was introduced in April 2019. As price tweaks will be…
HOME > BUSINESS
BUSINESS
- Kowa Seeks 5.6 Billion Yen in Add’l Damages from Towa over Livalo Generics
April 6, 2021
- Viatris Launches New Headquarters in Tokyo
April 6, 2021
- Toho to Supply Nafamostat Free of Charge to Italian Physician-Led COVID-19 Trial
April 6, 2021
- Mochida’s Updated 3-Year Biz Plan Vows Continued Focus on New Meds
April 5, 2021
- Suzuken Unit Wins Wholesale Contract for Incyte’s Pemazyre
April 5, 2021
- Taiho’s Cholangiocarcinoma Drug Gets Breakthrough Therapy Tag from FDA
April 5, 2021
- Houng Kim to Lead Celltrion Healthcare Japan
April 5, 2021
- Takeda/CSL-Led Alliance’s COVID-19 Plasma Therapy Fails in PIII
April 5, 2021
- GSK Sees Promise in Antibody Therapy against Coronavirus Variants, Looking at Japan Rollout Too
April 2, 2021
- Alinamin Aims for Growth via Retail Promotion, Full Entry into Asia: President
April 2, 2021
- ASKA Sets Up Office in London
April 2, 2021
- Takeda Wraps Up Divestment of European OTC Biz
April 2, 2021
- Takeda Completes Divestment of 4 Diabetes Meds to Teijin in Japan
April 2, 2021
- Mitsubishi Tanabe Wins US Patent Suit on Canagliflozin
April 2, 2021
- Viatris, Astellas to Wind Up Lipitor Copromotion at July-End
April 2, 2021
- Sandoz Shooting for Top Foreign Player in Japan Generic Market by 2023
April 1, 2021
- Fujifilm Holdings Names Teiichi Goto New President
April 1, 2021
- Eisai Snags Rights to Vibegron in 4 ASEAN States
April 1, 2021
- Takeda Completes Divestment of Consumer Healthcare Unit to Blackstone
April 1, 2021
- Eisai/MSD File Lenvima-Keytruda Pair in Japan, Seeking 1st Nod for RCC
April 1, 2021
ページ
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
After decades in recruitment, I say from experience that there’s a particular way to attract candidates to a given role. Do it right, and you’ll have talent chasing you. Get it wrong, and you’ll be left listening to the crickets…